Phases and phenotypes of multiple sclerosis

Research output: Contribution to journalReview article

Abstract

PURPOSE OF REVIEW This article describes the dynamic evolution of multiple sclerosis (MS) through its phases and the impact of this understanding on treatment decisions. RECENT FINDINGS MS consists of three phases: (1) the high-risk phase, (2) the relapsing-remitting phase, and (3) the progressive phase. Increasingly, subclinical disease activity is becoming an integral part of our definition of disease course in MS. In many patients, the relapsing-remitting phase starts as subclinical activity, likely long before they present with a clinically isolated syndrome. Differentiating progressive MS subgroups is also becoming less relevant. This is illustrated by comparing progressive MS that evolves from an asymptomatic state in individuals with radiologically isolated syndrome (primary progressive MS) and symptomatic individuals with relapsing-remitting MS (secondary progressive MS). In each case, the background disease activity and pathology can be indistinguishable. These phases evolve on a continuum and largely follow the aging process with little influence by the preceding clinical activity level. Recently, it also became evident that one or a few poorly recovered relapses at the beginning of clinical manifestations of MS predict much earlier progressive MS onset. SUMMARY These findings suggest that interventions to prevent progressive MS, when they become available for clinical practice, may need to be considered as early as when the asymptomatic radiologically isolated syndrome is detected. This early treatment approach is being evaluated with ongoing trials with available disease-modifying therapies. In contrast, continuing the use of disease-modifying therapy beyond a certain age may have little benefit. However, being in the progressive phase of MS is not, in itself, an argument against disease-modifying therapy use in active disease in younger patients.

Original languageEnglish (US)
Pages (from-to)636-654
Number of pages19
JournalCONTINUUM Lifelong Learning in Neurology
Volume25
Issue number3
DOIs
StatePublished - Jun 1 2019

Fingerprint

Multiple Sclerosis
Phenotype
Chronic Progressive Multiple Sclerosis
Therapeutics
Asymptomatic Diseases
Relapsing-Remitting Multiple Sclerosis
Pathology
Recurrence

ASJC Scopus subject areas

  • Clinical Neurology
  • Genetics(clinical)

Cite this

Phases and phenotypes of multiple sclerosis. / Kantarci, Orhun H.

In: CONTINUUM Lifelong Learning in Neurology, Vol. 25, No. 3, 01.06.2019, p. 636-654.

Research output: Contribution to journalReview article

@article{90b78d60fd824f5ea12db96b090267cc,
title = "Phases and phenotypes of multiple sclerosis",
abstract = "PURPOSE OF REVIEW This article describes the dynamic evolution of multiple sclerosis (MS) through its phases and the impact of this understanding on treatment decisions. RECENT FINDINGS MS consists of three phases: (1) the high-risk phase, (2) the relapsing-remitting phase, and (3) the progressive phase. Increasingly, subclinical disease activity is becoming an integral part of our definition of disease course in MS. In many patients, the relapsing-remitting phase starts as subclinical activity, likely long before they present with a clinically isolated syndrome. Differentiating progressive MS subgroups is also becoming less relevant. This is illustrated by comparing progressive MS that evolves from an asymptomatic state in individuals with radiologically isolated syndrome (primary progressive MS) and symptomatic individuals with relapsing-remitting MS (secondary progressive MS). In each case, the background disease activity and pathology can be indistinguishable. These phases evolve on a continuum and largely follow the aging process with little influence by the preceding clinical activity level. Recently, it also became evident that one or a few poorly recovered relapses at the beginning of clinical manifestations of MS predict much earlier progressive MS onset. SUMMARY These findings suggest that interventions to prevent progressive MS, when they become available for clinical practice, may need to be considered as early as when the asymptomatic radiologically isolated syndrome is detected. This early treatment approach is being evaluated with ongoing trials with available disease-modifying therapies. In contrast, continuing the use of disease-modifying therapy beyond a certain age may have little benefit. However, being in the progressive phase of MS is not, in itself, an argument against disease-modifying therapy use in active disease in younger patients.",
author = "Kantarci, {Orhun H}",
year = "2019",
month = "6",
day = "1",
doi = "10.1212/CON.0000000000000737",
language = "English (US)",
volume = "25",
pages = "636--654",
journal = "Continuum (Minneapolis, Minn.)",
issn = "1080-2371",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Phases and phenotypes of multiple sclerosis

AU - Kantarci, Orhun H

PY - 2019/6/1

Y1 - 2019/6/1

N2 - PURPOSE OF REVIEW This article describes the dynamic evolution of multiple sclerosis (MS) through its phases and the impact of this understanding on treatment decisions. RECENT FINDINGS MS consists of three phases: (1) the high-risk phase, (2) the relapsing-remitting phase, and (3) the progressive phase. Increasingly, subclinical disease activity is becoming an integral part of our definition of disease course in MS. In many patients, the relapsing-remitting phase starts as subclinical activity, likely long before they present with a clinically isolated syndrome. Differentiating progressive MS subgroups is also becoming less relevant. This is illustrated by comparing progressive MS that evolves from an asymptomatic state in individuals with radiologically isolated syndrome (primary progressive MS) and symptomatic individuals with relapsing-remitting MS (secondary progressive MS). In each case, the background disease activity and pathology can be indistinguishable. These phases evolve on a continuum and largely follow the aging process with little influence by the preceding clinical activity level. Recently, it also became evident that one or a few poorly recovered relapses at the beginning of clinical manifestations of MS predict much earlier progressive MS onset. SUMMARY These findings suggest that interventions to prevent progressive MS, when they become available for clinical practice, may need to be considered as early as when the asymptomatic radiologically isolated syndrome is detected. This early treatment approach is being evaluated with ongoing trials with available disease-modifying therapies. In contrast, continuing the use of disease-modifying therapy beyond a certain age may have little benefit. However, being in the progressive phase of MS is not, in itself, an argument against disease-modifying therapy use in active disease in younger patients.

AB - PURPOSE OF REVIEW This article describes the dynamic evolution of multiple sclerosis (MS) through its phases and the impact of this understanding on treatment decisions. RECENT FINDINGS MS consists of three phases: (1) the high-risk phase, (2) the relapsing-remitting phase, and (3) the progressive phase. Increasingly, subclinical disease activity is becoming an integral part of our definition of disease course in MS. In many patients, the relapsing-remitting phase starts as subclinical activity, likely long before they present with a clinically isolated syndrome. Differentiating progressive MS subgroups is also becoming less relevant. This is illustrated by comparing progressive MS that evolves from an asymptomatic state in individuals with radiologically isolated syndrome (primary progressive MS) and symptomatic individuals with relapsing-remitting MS (secondary progressive MS). In each case, the background disease activity and pathology can be indistinguishable. These phases evolve on a continuum and largely follow the aging process with little influence by the preceding clinical activity level. Recently, it also became evident that one or a few poorly recovered relapses at the beginning of clinical manifestations of MS predict much earlier progressive MS onset. SUMMARY These findings suggest that interventions to prevent progressive MS, when they become available for clinical practice, may need to be considered as early as when the asymptomatic radiologically isolated syndrome is detected. This early treatment approach is being evaluated with ongoing trials with available disease-modifying therapies. In contrast, continuing the use of disease-modifying therapy beyond a certain age may have little benefit. However, being in the progressive phase of MS is not, in itself, an argument against disease-modifying therapy use in active disease in younger patients.

UR - http://www.scopus.com/inward/record.url?scp=85066760652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066760652&partnerID=8YFLogxK

U2 - 10.1212/CON.0000000000000737

DO - 10.1212/CON.0000000000000737

M3 - Review article

C2 - 31162309

AN - SCOPUS:85066760652

VL - 25

SP - 636

EP - 654

JO - Continuum (Minneapolis, Minn.)

JF - Continuum (Minneapolis, Minn.)

SN - 1080-2371

IS - 3

ER -